HeartBeam Inc. (NASDAQ: BEAT) announced the closing of its underwritten public offering of 12.5 million shares of common stock, generating gross proceeds of $10 million before expenses. The transaction, completed on April 16, 2026, was supported by key stakeholders including ClearCardio, company leadership and institutional investors. The funds will be directed toward the commercialization of HeartBeam’s FDA-cleared 12-lead synthesized ECG system, further development of its extended-wear patch and heart attack detection technologies, expansion of AI capabilities and general corporate purposes.
This capital infusion arrives at a pivotal time for the company, which is pioneering the first cable-free device capable of collecting ECG signals in 3D from three non-coplanar directions and synthesizing them into a standard 12-lead ECG. The platform technology is designed for portable use, enabling physicians to identify cardiac health trends and acute conditions outside of medical facilities. HeartBeam’s 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024, and its 12-lead ECG synthesis software received clearance in December 2025. The company holds over 20 issued patents related to technology enablement.
“We are pleased to have successfully closed this offering, which we believe positions HeartBeam to execute on our strategic objectives,” said the company in a statement. The offering’s closure is expected to accelerate the rollout of HeartBeam’s AI-enhanced cardiac monitoring solutions, potentially transforming how critical cardiac conditions are detected and managed. The company’s technology aims to deliver actionable heart intelligence wherever the patient is, redirecting care pathways and reducing reliance on traditional, facility-based ECG systems.
For more details on the offering, the full press release is available at https://ibn.fm/9iNYY. HeartBeam’s cleared indications for use can be found at https://www.heartbeam.com/indications. The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT.
HeartBeam, Inc. is a medical technology company dedicated to transforming the detection and monitoring of critical cardiac conditions. Its platform technology is designed for portable devices that can be used wherever the patient is, redefining the future of cardiac health management. The successful capital raise underscores investor confidence in HeartBeam’s technology and its potential to disrupt the cardiac monitoring market.
